Intensive Care Department, The Canberra Hospital, Canberra, Australia.
Ann Intensive Care. 2011 Nov 1;1(1):44. doi: 10.1186/2110-5820-1-44.
This study was designed to investigate the effect of hypertonic fluid administration on inflammatory mediator gene expression in patients with septic shock.
Prospective, randomized, controlled, double-blind clinical study in a 15-bed mixed intensive care unit in a tertiary referral teaching hospital.
Twenty-four patients, who met standard criteria for septic shock, were randomized to receive a bolus of hypertonic fluid (HT, 250 ml 6% HES/7.2% NaCl) or isotonic fluid (IT, 500 ml 6% HES/0.9% NaCl) administered over 15 minutes. Randomization and study fluid administration was within 24 hours of ICU admission for all patients. This trial is registered with ANZCTR.org.au as ACTRN12607000259448.
Blood samples were taken immediately before and 4, 8, 12, and 24 hours after fluid administration. Real-time reverse transcriptase polymerase chain reaction (RT rtPCR) was used to quantify mRNA expression of different inflammatory mediators in peripheral leukocytes. In the HT group, compared with the IT group, levels of gene expression of MMP9 and L-selectin were significantly suppressed (p = 0.0002 and p = 0.007, respectively), and CD11b gene expression tended to be elevated (p = NS). No differences were found in the other mediators examined.
In septic shock patients, hypertonic fluid administration compared with isotonic fluid may modulate expression of genes that are implicated in leukocyte-endothelial interaction and capillary leakage.The study was performed at the Intensive Care Department, Waikato Hospital, and at the Molecular Genetics Laboratory, University of Waikato, Hamilton, New Zealand.
Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12607000259448.
本研究旨在探讨高渗液治疗对感染性休克患者炎症介质基因表达的影响。
在一家三级转诊教学医院的 15 张混合重症监护病房进行的前瞻性、随机、对照、双盲临床研究。
24 名符合感染性休克标准的患者被随机分为高渗液(HT,250 ml 6% HES/7.2% NaCl)或等渗液(IT,500 ml 6% HES/0.9% NaCl)组,均在 ICU 入院后 24 小时内接受 15 分钟的推注。本试验在澳大利亚新西兰临床试验注册中心(ANZCTR)注册,注册号为 ACTRN12607000259448。
在液体输注前和输注后 4、8、12 和 24 小时采集血样。实时逆转录聚合酶链反应(RT rtPCR)用于定量外周白细胞中不同炎症介质的 mRNA 表达。与 IT 组相比,HT 组 MMP9 和 L-选择素的基因表达水平显著降低(p = 0.0002 和 p = 0.007),CD11b 基因表达水平升高(p = NS)。在其他检查的介质中未发现差异。
在感染性休克患者中,与等渗液相比,高渗液治疗可能调节白细胞-内皮相互作用和毛细血管渗漏相关基因的表达。该研究在新西兰怀卡托医院的重症监护病房和怀卡托大学的分子遗传学实验室进行。
澳大利亚和新西兰临床试验注册中心(ANZCTR):ACTRN12607000259448。